Pharmacotherapeutic targeting of the endocannabinoid signaling system: Drugs for obesity and the metabolic syndrome

Physiology and Behavior

Volumn 93, Issue 4-5, 2008, Pages 671-686

  Vemuri, V Kiran ^a   Janero, David R ^a   Makriyannis, Alexandros ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Addiction; Antagonist; Appetitive behavior; Cardiometabolic risk; Cardiovascular disease; Diet; Drugs; Endocannabinoid; Inverse agonist; Ligands; Metabolic syndrome; Neutral antagonist; Obesity; Receptor; Rimonabant; Weight management

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (4 BROMOPHENYL) 1 (2,4 DICHLOROPHENYL) 4 ETHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; ALLI; ANTINEOPLASTIC AGENT; AVE 1625; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABIS; DRONABINOL; METHAMPHETAMINE; NABILONE; PHENTERMINE; PHENTERMINE RESIN; PLACEBO; RIMONABANT; SCOPOLAMINE; SIBUTRAMINE; TARANABANT; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGGRESSION; ANALGESIA; ANXIETY; ARTICLE; BRAIN DAMAGE; CACHEXIA; CANCER PAIN; CARDIOTOXICITY; CHEMICAL STRUCTURE; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; FEEDING BEHAVIOR; FOOD INTAKE; GASTROINTESTINAL TOXICITY; GILLES DE LA TOURETTE SYNDROME; GLAUCOMA; HEALTH HAZARD; HUMAN; HYPOGLYCEMIA; IN VIVO STUDY; INFLAMMATION; LIPOGENESIS; METABOLIC SYNDROME X; MULTIPLE SCLEROSIS; MUSCULAR DYSTROPHY; NAUSEA; NAUSEA AND VOMITING; NEOPLASM; NEUROPATHIC PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PARKINSON DISEASE; PHASE 3 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUICIDE ATTEMPT; TOBACCO DEPENDENCE; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 40949112752     PISSN: 00319384     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.physbeh.2007.11.012     Document Type: Article

References (159)

1. Pertwee R.G. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol 147 (2006) S163-S171
2. Mechoulam R. Discovery of endocannabinoids and some random thoughts on their possible roles in neuroprotection and aggression. Prostaglandins Leukot Essent Fat Acids 66 (2002) 93-99
3. Grotenhermen F. Pharmacology of cannabinoids. Neuro Endocrinol Lett 25 (2004) 14-23
4. Ameri A. The effects of cannabinoids on the brain. Prog Neurobiol 58 (1999) 315-348
5. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., et al. International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54 (2002) 161-202
6. Pertwee R.G. The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes 30 (2006) S13-S18
7. Onaivi E.S., Ishiguro H., Gong J.P., Patel S., Perchuk A., Meozzi P.A., et al. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann NY Acad Sci 1074 (2006) 514-536
8. Devane W.A., Hanhus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 (1992) 1946-1949
9. Mechoulam R., Benshabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50 (1995) 83-90
10. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215 (1995) 89-97
11. Di Marzo V., and Petrosino S. Endocannabinoids and the regulation of their levels in health and disease. Curr Opin Lipidol 18 (2007) 129-140
12. Matias I., and Di Marzo V. Endocannabinoid synthesis and degradation, and their regulation in the framework of energy balance. J Endocrinol Invest 29 (2006) 15-26
13. Demuth D.G., and Molleman A. Cannabinoid signaling. Life Sci 78 (2006) 549-563
14. Childers S.R. Activation of G-proteins in brain by endogenous and exogenous cannabinoids. AAPS J 8 (2006) E112-E117
15. Oz M. Receptor-independent actions of cannabinoids on cell membranes: focus on endocannabinoids. Pharmacol Ther 111 (2006) 114-144
16. Fowler C.J. The cannabinoid system and its pharmacological manipulation-a review, with emphasis upon the uptake and hydrolysis of anandamide. Fundam Clin Pharmacol 20 (2006) 549-562
17. Mackie K., and Stella N. Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J 8 (2006) E298-E306
18. Basavarajappa B.S. Critical enzymes involved in endocannabinoid metabolism. Protein Pept Lett 14 (2007) 237-246
19. Liu J, Wang L, Harvey-White J, Huang BX, Kim HY, Luquet S, Palmiter RD, Krystal G, Rai R, Mahadevan A, Razdan RK, Kunos G. Multiple pathways involved in the biosynthesis of anandamide. Neuropharmacology in press. doi:10.1016/j.neuropharm.2007.05.020.
20. Sugiura T., Kishimoto S., Oka S., and Gokoh M. Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Prog Lipid Res 45 (2006) 405-446
21. Ligresti A., Cascio M.G., and Di Marzo V. Endocannabinoid metabolic pathways and enzymes. Curr Drug Targets CNS Neurol Disord 4 (2005) 615-623
22. Ho W.S., and Randall M.D. Endothelium-dependent metabolism by endocannabinoid hydrolases and cyclooxygenases limits vasorelaxation to anandamide and 2-arachidonoylglycerol. Br J Pharmacol 150 (2007) 641-651
23. Pacher P., Bátaki S., and Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58 (2006) 389-462
24. Hashimotodani Y., Ohno-Shosaku T., and Kano M. Endocannabinoids and synaptic function in the CNS. Neuroscientist 13 (2007) 127-137
25. Khanapure S.P., Garvey D.S., Janero D.R., and Letts L.G. Eicosanoids in inflammation: biosynthesis, pharmacology, and therapeutic frontiers. Curr Topics Med Chem 7 (2007) 311-340
26. Bari M., Battista N., Fezza F., Gasperi V., and Maccarrone M. New insights into endocannabinoid degradation and its therapeutic potential. Mini Rev Med Chem 6 (2006) 257-268
27. Bisogno T., Cascio M.G., Saha B., Mahadevan A., Urbani P., Minassi A., et al. Development of the first potent and specific inhibitors of endocannabinoid biosynthesis. Biochim Biophys Acta 1761 (2006) 205-212
28. Karanian D.A., Brown Q.B., Makriyannis A., Kosten T.A., and Bahr B.A. Dual modulation of endocannabinoid transport and fatty acid amide hydrolase protects against excitotoxicity. J Neurosci 25 (2005) 7813-7820
29. Kaczocha M., Hermann A., Glaser S.T., Bojesen I.N., and Deutsch D.G. Anandamide uptake is consistent with rate-limited diffusion and is regulated by the degree of its hydrolysis by fatty acid amide hydrolase. J Biol Chem 281 (2006) 9066-9075
30. Puffenbarger R.A. Molecular biology of the enzymes that degrade endocannabinoids. Curr Drug Targets CNS Neurol Disord 4 (2005) 625-631
31. Karanian D.A., Karim S.L., Wood J.T., Williams J.S., Lin S., Makriyannis A., and Bahr B.A. Endocannabinoid enhancement protects against kainic acid-induced seizures and associated brain damage. J Pharmacol Exp Ther 322 (2007) 1059-1066
32. Flanagan J.M., Gerber A.l., Cadet J.L., Beutler E., and Sipe J.C. The fatty acid amide hydrolase 385 A/A (P129T) variant: haplotype analysis and validation of risk for drug addiction. Hum Genet 120 (2006) 581-588
33. Makie K. Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol 46 (2006) 101-122
34. Pavlopoulos S., Thakur G.A., Nikas S.P., and Makriyannis A. Cannabinoid receptors as therapeutic targets. Curr Pharm Des 12 (2006) 1751-1769
35. Wilkinson J.D., and Williamson E.M. Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis. J Dermatol Sci 45 (2007) 87-92
36. Ibrahim M.M., Rude M.L., Stagg N.J., Mata H.P., Lai J., Vanderah T.W., et al. CB2 cannabinoid receptor mediation of antinociception. Pain 122 (2006) 36-42
37. Thakur G.A., Duclos Jr. R.I., and Makriyannis A. Natural cannabinoids: templates for drug discovery. Life Sci 78 (2005) 454-466
38. Xu W., Filppula S.A., Mercier R., Yaddanapudi S., Pavlopoulos S., Cai J., et al. Purification and mass spectroscopic analysis of human CB1 cannabinoid receptor functionally expressed using the baculovirus system. J Pept Res 66 (2005) 138-150
39. Zvonok N., Yaddanapudi S., Williams J., Dai S., Dong K., Rejtar T., et al. Comprehensive proteomic mass spectrophotometric characterization of human cannabinoid CB2 receptor. J Proteome Res 6 (2007) 2068-2079
40. Di Marzo V., Bifulco M., and De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nature Rev Drug Dis 3 (2004) 771-784
41. Sativex receives qualifying notice for approval in Canada for the relief of cancer pain. Available at (August, 2007). http://www.gwpharma.com/news_press_releases.asp Accessed
42. GW EU regulatory withdrawal. Available at (August, 2007). http://www.gwpharma.com/news_press_releases.asp Accessed
43. GW and Otsuka enter into global cannabinoid research collaboration. Available at (August, 2007). http://www.gwpharma.com/news_press_releases.asp Accessed
44. Henness S., Robinson D.M., and Lyseng-Williamson K.A. Rimonabant. Drugs 66 (2006) 2109-2119
45. Tucci S.A., Halford J.C., Harrold J.A., and Kirkham T.C. Therapeutic potential of targeting the endocannabinoids: implications for the treatment of obesity, metabolic syndrome, drug abuse and smoking cessation. Curr Med Chem 13 (2006) 2669-2680
46. Le Foll B., and Goldberg S.R. Cannabinoid CB1 receptor antagonist as promising new medications for drug dependence. J Pharmacol Exp Ther 312 (2005) 875-883
47. Lan R., Liu Q., Fan P., Lin S., Fernando S.R., McCallion D., et al. Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J Med Chem 42 (1999) 769-776
48. Lan R., Gatley J., Lu Q., Fan P., Fernando S.R., Volkow N.D., et al. Design and synthesis of the CB1 selective cannabinoid antagonist AM281: a potential human SPECT ligand. AAAP PharmSci 1 (1999) E4
49. Baumer J.H. Obesity and overweight: its prevention, identification, assessment and management. Arch Dis Child Educ Pract Ed 92 (2007) 92-96
50. Mascie-Taylor C.G., and Goto R. Human variations and body mass index: a review of the universality of BMI cut-offs, gender and urban-rural differences, and secular changes. J Physiol Anthropol 26 (2007) 109-112
51. Hofbauer K.G., Nicholson J.R., and Boss O. The obesity epidemic: current and future pharmacological treatments. Annu Rev Pharmacol Toxicol 47 (2007) 565-592
52. The Science of Appetite. Time, June 11, 2007. Available at (August, 2007). http://www.time.com/magazine/article/0,9171,1627006,00.html Accessed
53. Hill J.O. Understanding and addressing the epidemic of obesity: an energy balance perspective. Endocr Rev 27 (2006) 750-761
54. PA-06-256: Exploratory/developmental clinical research grants in obesity (R21). Posted March 17, 2006. Available athttp://grants.nih.gov/grants/guide/pa-files/PA-06-256.htmlAccessed August, 2007.
55. Padwal R.S., and Majumdar S.R. Drug treatments for obesity: orlistat, sibutramine and rimonabant. Lancet 369 (2007) 71-77
56. Brethauer S.A., Chand B., and Schauer P.R. Risks and benefits of bariatric surgery: current evidence. Cleve Clin J Med 73 (2006) 993-1007
57. Chaput J.P., St-Pierre S., and Tremblay A. Currently available drugs for the treatment of obesity: sibutramine and orlistat. Mini Rev Med Chem 7 (2007) 3-10
58. Bray G.A., and Ryan D.H. Drug treatment of the overweight patient. Gastroenterology 132 (2007) 2239-2252
59. Cooke D., and Bloom S. The obesity pipeline: current strategies in the development of anti-obesity drugs. Nat Rev Drug Disc 5 (2006) 919-931
60. Grundy S.M., Cleeman J.I., Merz N.B., Brewer H.B., Clark L.T., Hunninghake D.B., et al. for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
61. Fernandez M.L. The metabolic syndrome. Nutr Rev 65 (2007) S30-S34
62. Katagiri H., Yamada T., and Oka Y. Adiposity and cardiovascular disorders: disturbance of the regulatory system consisting of humoral and neuronal signals. Circ Res 101 (2007) 27-39
63. Ogden C.L., Yanovski S.Z., Carroll M.D., and Flegal K.M. The epidemiology of obesity. Gastroenterology 132 (2007) 2087-2102
64. Christakis N.A., and Fowler J.H. The spread of obesity in a large social network over 32 years. N Engl J Med 357 (2007) 370-379
65. Jones L.R., Wilson C.I., and Wadden T.A. Lifestyle modification in the treatment of obesity: an educational challenge and opportunity. Clin Pharmacol Ther 81 (2007) 776-779
66. Janero D.R. Nutritional spects of nitric oxide: human health implications and therapeutic opportunities. Nutrition 17 (2001) 896-903
67. Coll A.P., Farooqui I.S., and O'Rahilly S. The hormonal control of food intake. Cell 129 (2007) 251-262
68. Pagotto U., Marsicano G., Cota D., Lutz B., and Pasquali R. The endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 27 (2006) 73-100
69. Cota D., Tschöp M.H., Horvath T.L., and Levine A.S. Cannabinoids, opioids and eating behavior: the molecular face of hedonism?. Brain Res Rev 51 (2006) 85-107
70. Bellocchio L., Mancini G., Vicennati V., Pasquali R., and Pagotto U. Cannabinoid receptors as therapeutic targets for obesity and metabolic diseases. Curr Opin Pharmacol 6 (2006) 586-591
71. Duffy D., and Rader D. Endocannabinoid antagonism: blocking the excess in the treatment of high-risk abdominal obesity. Trends Cardiovasc Med 17 (2007) 35-43
72. Ametamey S.M., and Honer M. Pharmacological prerequisites for PET ligands and practical issues in preclinical PET research. Ernst Schering Res Found Workshop 62 (2007) 317-327
73. 123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors. Eur J Pharmacol 307 (1996) 331-338
74. 124I]AM281 PET demonstrated in a schizophrenic patient. Psychiatry Res 147 (2006) 249-256
75. 125/131I]AM2233. Synapse 60 (2006) 93-101
76. 18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc Natl Acad Sci USA 104 (2007) 9800-9805
77. Imaging of cannabinoid receptors using new radioactive tracer. Available at (August, 2007). http://clinical trials.gov/show/NCT00450021 Accessed
78. Carpino PA, Sanner MA. Cannabinoid receptor ligands and uses thereof. WO patent 2007;2007/020502.
79. A 2-year, randomized, double-blind, placebo controlled, phase 3 study to evaluate the long-term efficacy and safety of CP-945,598 in the treatment of obese subjects. Available at (August, 2007). http://clinical trials.gov/show/NCT00375401 Accessed
80. Janero D.R., and Makriyannis A. Targeted modulators of the endogenous cannabinoid system: future medications to treat addiction disorders and obesity. Curr Psychiatry Rep 9 (2007) 365-373
81. Boyd A.T., and Fremming B.A. Rimonabant-a selective CB1 antagonist. Ann Pharmacother 39 (2005) 684-690
82. Patel P.N., and Pathak R. Rimonabant: a novel selective cannabinoid-1 receptor antagonist for treatment of obesity. Am J Health Syst Pharm 64 (2007) 481-489
83. Kakafika A.I., Mikhailidis D.P., Karagiannis A., and Athyros V.G. The role of endocannabinoid system blockade in the treatment of the metabolic syndrome. J Clin Pharmacol 47 (2007) 642-652
84. Szmitko P.E., Teoh H., Stewart D., and Verma S. Adiponectin and cardiovascular disease: state of the art?. Am J Physiol 292 (2007) H1655-H1663
85. Despres J.P., Golay A., Sjostrom L., and for the Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353 (2005) 2121-2134
86. Van Gaal L.F., Rissanen A.M., Scheen A.J., Ziegler O., Rossner S., and for the RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365 (2005) 1389-1397
87. Pi-Sunyer F.X., Aronne L.J., Heshmati H.M., Devin J., Rosenstock J., and for the RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. JAMA 295 (2006) 761-775
88. Scheen A.J., Finer N., Hollander P., Jensen M.D., Van Gaal L.F., and RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes. Lancet 368 (2006) 1160-1172
89. Wierzbicki A.S. Rimonabant: endocannabinoid inhibition for the metabolic syndrome. Int J Clin Pract 60 (2006) 1697-1706
90. Reid R.D., Quinlan B., Riley D.L., and Pipe A.L. Smoking cessation: lessons learned from clinical trial evidence. Curr Opin Cardiol 22 (2007) 280-285
91. Rimonabant regulatory update in the United States. Available at (August, 2007). http://en.sanofi-aventis.com/Images/070629_rimonabant-US_en_tcm24-17003. pdf Accessed
92. SR141716 Zimulti (rimonabant) NDA 21-888. Briefing information for FDA advisory committee meeting. Available at (August, 2007). http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4306b1-01-sponsor-b ackgrounder.htm Accessed
93. Allī - the OTC weight loss product - on shelves nationwide later this week. Available at (August, 2007). http://us.gsk.com/ControllerServlet?appId=4&pageId=402&newsid=11 03 Accessed
94. CRESCENDO. Comprehensive rimonabant evaluation study of cardiovascular endpoints and outcomes. 2005. Available at (August, 2007). http://www.clinicaltrials.gov/ct/show/NCT00263042 Accessed
95. STRADIVARIUS. Strategy to reduce atherosclerosis development involving administration of rimonabant-the intravascular ultrasound study. 2005. Available at (August, 2007). http://www.clinicaltrials.gov/ct/show/NCT00124332 Accessed
96. VENUS. Japanese study of rimonabant in obese patients with dyslipidemia. 2007. Available at (August, 2007). http://www.clinicaltrials.gov/ct/show/NCT00434096 Accessed
97. SYMPHONY. Japanese study with rimonabant on obese type 2 diabetic patients with oral anti-diabetic drug. 2007. Available at (August, 2007). http://www.clinicaltrials.gov/ct/show/NCT00478595 Accessed
98. SOLO. Japanese study with rimonabant in obese type 2 diabetic patients on diet and exercise. Available at (August, 2007). http://www.clinicaltrials.gov/ct/show/NCT00478972 Accessed
99. Plummer C.W., Finke P.E., Mills S.G., Wang J., Tong X., Doss G.A., et al. Synthesis and activity of 4,5-diarylimidazoles as human CB1 receptor inverse agonists. Bioorg Med Chem Lett 15 (2005) 1441-1446
100. Carpino P.A., Griffith D.A., Sakya S., Dow R.L., Black S.C., Hadcock J.R., et al. New bicyclic cannabinoid receptor-1 (CB1-R) antagonists. Bioorg Med Chem Lett 16 (2006) 731-736
101. Lagu B, Liotta F, Pan M, Wachter MP, Xia M. Tetrahydroindazole cannabinoid modulators. WO Patent 2005;2005/095353.
102. Shim J.Y., Welsh W.J., Cartier E., Edwards J.L., and Howlett A.C. Molecular interaction of the antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H -pyrazole-3-carboxamide with the CB1 cannabinoid receptor. J Med Chem 45 (2002) 1447-1459
103. Hurst D.P., Lynch D.L., Barnett-Norris J., Hyatt S.M., Seltzman H.H., Zhong M., et al. N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H -p yrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor. Mol Pharmacol 62 (2002) 1274-1287
104. Hurst D., Umejiego U., Lynch D., Seltzman H., Hyatt S., Roche M., et al. Biarylpyrazole inverse agonists at the cannabinoid CB1 receptor: importance of the C-3 carboxamide oxygen/lysine3.28(192) interaction. J Med Chem 49 (2006) 5969-5987
105. Smith R.A., Fathi Z., Brown S.E., Choi S., Fan J., Jenkins S., et al. Constrained analogs of CB-1 antagonists: 1,5,6,7-Tetrahydro-4H-pyrrolo[3,2-c]pyridine-4-one derivatives. Bioorg Med Chem Lett 17 (2007) 673-678
106. Cheng L. Preparation and use of tetrahydropyrrolo[3,2-C]pyridine-4-one derivatives for treatment of obesity, psychiatric and neurological disorders. WO Patent 2007;2007/039740.
107. Smith RA, Wong WC, O'Connor SJ, Choi S, Kluender HCE, Zhang Z, Lavoie RC, Fan J, Podlogar BL. Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity. 2004;WO Patent 2003 2003/027114.
108. Debenham J.S., Madsen-Duggan C.B., Walsh T.F., Wang J., Tong X., Doss G.A., et al. Synthesis of functionalized 1,8-napthyridiones and their evaluation as novel, orally active CB1 receptor inverse agonists. Bioorg Med Chem Lett 16 (2006) 681-685
109. Davidson JEP, Dawson CE, Harrison K, Mansell HL, Pratt RM, Sohal S, Ruston VJ. Azetidinecarboxamide derivatives and their use in the treatment of CB1 receptor-mediated disorders. 2004;WO Patent 2004/096763.
110. Lin L.S., Lanza Jr. T.J., Jewell J.P., Liu P., Shah S.K., Qi H., et al. Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl -2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity. J Med Chem 49 (2006) 7584-7587
111. Fong T.M., Guan X.M., Marsh D.J., Shen C.P., Stribling D.S., Rosko K.M., et al. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl -2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents. J Pharmacol Exp Ther 321 (2007) 1013-1022
112. Taranabant approved as generic name for MK-0364. Available at (August, 2007). http://www.merck.com/newsroom/press_releases/research_and_development/20 07_0226.html Accessed
113. Rinaldi-Carmona M., Barth F., Congy C., Martinez S., Oustric D., Perio A., et al. SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-p yr azole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization. J Pharmacol Exp Ther 310 (2004) 905-914
114. Gessa G.L., Serra S., Vacca G., Carai M.A., and Colombo G. Suppressing effect of the cannabinoid CB1 receptor antagonist, SR147778, on alcohol intake and motivational properties of alcohol in alcohol-preferring sP rats. Alcohol Alcohol 40 (2005) 46-53
115. Lallemand F., and De Witte P. SR147778, a CB1 cannabinoid receptor antagonist, suppresses ethanol preference in chronically alcoholized Wistar rats. Alcohol 39 (2006) 125-134
116. SURSMOKE. Efficacy and safety of surinabant treatment as an aid to smoking cessation. Available at (August, 2007). http://www.clinicaltrials.gov/ct/show/NCT00432575 Accessed
117. Lange J.H., Coolen H.K., van Stuivenberg H.H., Dijksman J.A., Herremans A.H., Ronken E., et al. Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists. J Med Chem 47 (2004) 627-643
118. Need A.B., Davis R.J., Alexander-Chacko J.T., Eastwood B., Chernet E., Phebus L.A., et al. The relationship of in vivo central CB1 receptor occupancy to changes in cortical monoamine release and feeding elicited by CB1 receptor antagonists in rats. Psychopharmacology (Berl) 184 (2006) 26-35
119. Lange J.H., van Stuivenberg H.H., Veerman W., Wals H.C., Stork B., Coolen H.K., et al. Novel 3,4-diarylpyrazolines as potent cannabinoid CB1 receptor antagonists with lower lipophilicity. Bioorg Med Chem Lett 15 (2005) 4794-4798
120. Solvay's obesity candidate treatment advances in phase II clinical trials. Available at (August, 2006). http://www.solvaypharmaceuticals.com/static/wma/pdf/9/3/1/3/20061208SLV3 19OBESITYEN.pdf Accessed
121. Diu-Hercend A., Suc-Royer I., Gallea S., Laville M., Rouyer T., Bohme G.A., and Benavides J. Binding profile and functional characterization of AVE1625, a novel cannabinoid CB1 receptor antagonist, Program Number 653.13 (2005), Society for Neuroscience, Washington, DC (Abstract)
122. Pratt J., Roux M., Stutzmann J.M., Piot-Grosjean O., and Benavides J. Effects of AVE1625, a novel cannabinoid CB1 antagonist, in models of aggression and depression. Program Number 653.16 (2005), Society for Neuroscience, Washington, DC (Abstract)
123. Piot-Grosjean O., Goniot P., Imbault F., Mazadier M., Miquet J.M., Obinu M.C., et al. In vivo effects of AVE1625, a novel cannabinoid CB1 receptor antagonist, on brain acetylcholine levels and in rodent models of learning and memory. Program Number 653.14 (2005), Society for Neuroscience, Washington, DC (Abstract)
124. Lopez-Ramos J., Bohne G.A., Piot-Grosjean O., Benavides J., and Delgado-Garcia J. Effects of AVE1625, a novel CB1 antagonist, on classical eyeblink conditioning in mice. Program Number 653.15 (2005), Society for Neuroscience, Washington, DC (Abstract)
125. Stutzmann J., Hill M., Pratt J., Bezard E., Piot-Grosjean O., Crossman A., et al. Antidyskinetic and prokinetic effects of AVE1625, a selective CB1 cannabinoid receptor antagonist, on rodent and primate models of Parkinson's disease. Program Number 175.5/HH8 (2006), Society for Neuroscience, Atlanta, Georgia (Abstract)
126. Zuurman L., Roy C., Schoemaker R.C., Asset G., Amatsaleh A., Guimaraes L., et al. Inhibition of THC-induced effects on central nervous system effects and heart rate by a novel CB1 receptor antagonist AVE1625. Br J Clin Pharmacol 63 Supplement (2007) 769 (Abstract)
127. CONNECT. Efficacy and safety of AVE1625 as a co-treatment with antipsychotic therapy in schizophrenia. Available at (August, 2007). http://www.clinicaltrials.gov/ct/show/NCT00439634 Accessed
128. Activity of AVE1625 in mild to moderate Alzheimer's patients. Available at (August, 2007). http://www.clinicaltrials.gov/ct/show/NCT00380302 Accessed
129. Herling A.W., Gossel M., Haschke G., Stengelin S., Kuhlmann J., Müeller G., Schmoll D., and Kramer W. The CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independent of reduced food intake in Wistar rats. Am J Physiol Endocrinol Metab 293 (2007) E826-E832
130. Dose-ranging study evaluating AVE1625 in abdominally obese patients with atherogenic dyslipidemia. Available at (August, 2007). http://www.clinicaltrials.gov/ct/show/NCT00345410 Accessed
131. Rimonabant to reduce alcohol consumption. Available at (August, 2007). http://www.clinicaltrials.gov/ct/show/NCT0075205 Accessed
132. Siegfried Z., Kanyas K., Latzer Y., Karni O., Bloch M., Lerer B., et al. Association study of cannabinoid receptor gene (CNR1) alleles and anorexia nervosa: differences between restricting and binging/purging subtypes. Am J Med Genet B Neuropsychiatr Genet 125 (2004) 126-130
133. Monteleone P., Matias I., Martiadis V., De Petrocellis L., Maj M., and Di Marzo V. Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology 30 (2005) 1216-1221
134. A clinical trial on the antipsychotic properties of cannabidiol. Available at (August, 2007). http://www.clinicaltrials.gov/ct/show/NCT00309413 Accessed
135. Cannabinoids in bipolar affective disorder. Available at (August, 2007). http://www.clinicaltrials.gov/ct/show/NCT00397605 Accessed
136. Ziedonis D.M., Smelson D., Rosenthal R.N., Batki S.L., Green A.I., Henry R.J., et al. Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations. J Psychiatr Pract 11 (2005) 315-319
137. Ohayon M.M. Epidemiology of depression and its treatment in the general population. J Psychiatr Res 41 (2007) 207-213
138. Sink KS, McLaughlin PJ, Wood JAT, Brown C, Fan P, Vemuri VK, Pang Y, Olzewska T, Thakur GA, Makriyannis A, Parker LA, Salamone JD. The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacol in press. doi:10.1007/s00213-007-0988-4.
139. Salamone J.D., McLaughlin P.J., Sink K., Makriyannis A., and Parker L.A. Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions. Physiol Behav 91 (2007) 383-388
140. Overington J.P., Al-Lazikani B., and Hopkins A.L. How many drug targets are there?. Nat Rev Drug Discov 5 (2006) 993-996
141. Ward S.J., and Dykstra L.A. The role of CB1 receptors in sweet versus fat reinforcement: effect of CB1 receptor deletion, CB1 receptor antagonism (SR141716A) and CB1 receptor agonism (CP-55,940). Behav Pharmacol 16 (2005) 381-388
142. Chen R.Z., Huang R.R.C., Shen C.P., MacNeil D.J., and Fong T.M. Synergistic effects of cannabinoid inverse agonist AM251 and opioid antagonist nalmefene on food intake in mice. Brain Res 999 (2004) 227-230
143. Odile P-G, Philippe P, Francois P. Combination of CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity. 2006;United States patent 7148258.
144. Jacobson PB, Brune ME, Bush EN, Opgenorth TJ, Collins CA, Von Geldern T. Sibutramine and rimonabant combination for treatment of obesity. 2006;WO Patent 2006/124506.
145. Odile P-G, Philippe P, Francois P. Combination of CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity. United States patent application 2006;2006/258709.
146. Antel J, Krause HG, Gregory P-C, Wurl M, Waldeck H, Lange JHM, Kruse CG. Combination treatment of obesity involving 4,5-dihydro-1H-pyrazole derivatives having CB1 antagonistic activity and lipase inhibitors. 2005;WO Patent 2005/039566.
147. Firnges M, Gregory P-C, Antel J, Lange JHM, Waldeck H. Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type I, obesity and related conditions. 2006;WO Patent 2006/045799.
148. Veltri EP. Combinations of substituted azetidinones and CB1 antagonists 2006;WO Patent 2006/039334.
149. Amatruda JM, Fong TM, Moller DE, Thornberry NA. Combination of dipeptidyl peptidase-IV inhibitor and a cannabinoid CB1 receptor antagonist for the treatment of diabetes and obesity. 2006;WO Patent 2006/119260.
150. Wren J.A., Ramudo A.A., Campbell S.L., King V.L., Eagleson J.S., Gossellin J., and Sunderland S.J. Efficacy and safety of dirlotapide in the management of obese dogs evaluated in two placebo-controlled, masked clinical studies in North America. J Vet Pharmacol Ther 30 Supppl 1 (2007) 81-89
151. FDA approves the first drug for obese dogs. Available at (August, 2007). http://www/fda.gov/bbs/topics/NEWS/2007/NEW01542.html Accessed
152. Schoffelmeer A.N.N., Hogenboom G., Wardeh G., and De Vries T.J. Interactions between CB1 cannabinoid and μ opioid receptors mediating inhibition of neurotransmitter release in rat nucleus accumbens core. Neuropharmacology 51 (2006) 773-781
153. Ellis J., Pediani J.D., Canals M., Milasta S., and Milligan G. Orexin-1 receptor-cannabinoid CB 1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function. J Biol Chem 281 (2006) 38812-38824
154. Sipe J.C., Waalen J., Gerber A., and Beutler E. Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH). Int J Obes 29 (2005) 755-759
155. Aberle J., Fedderwitz I., Klages N., George E., and Beil F.U. Genetic variation in two proteins of the endocannabinoid system and their influence on body mass index and metabolism under low fat diet. Horm Metab Res 39 (2007) 395-397
156. Fegley D., Gaetani S., Duranti A., Tontine A., Mor M., Tarzia G., and Piomelli D. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-3-yl ester (URB597): effects of anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther 313 (2005) 352-358
157. Serrano A, Del Arco I, Javier Pavón F, Macías M, Perez-Valero V, Roderíguez de Fonseca F. The cannabinoid CB1 receptor antagonist SR141716A (rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats. Neuropharmacology in press. doi:10.1016/j.neuropharm.2007.03.007.
158. Kapur A., Hurst D.P., Fleischer D., Whitnell R., Thakur G.A., Makriyannis A., Reggio P.H., and Abood M.E. Mutation studies of Ser7.39 and ser2.60 in the human CB1 cannabinoid receptor: evidence for a serine-induced bend in CB1 transmembrane helix 7. Mol Pharmacol 71 (2007) 1512-1524
159. Williams J., Wood J., Pandarinathan L., Karanian D.A., Bahr B.A., Vouros P., and Makriyannis A. Quantitative method for the profiling of the endocannabinoid metabolome by LC-atmosphere pressure chemical ionization-MS. Anal Chem 79 (2007) 5582-5593